Is centralisation of head and neck cancer services a cost effective option? The London experience

2017 ◽  
Vol 46 ◽  
pp. 375
Author(s):  
K. Tzanidakis ◽  
Z. Sadiq ◽  
N. Kalavrezos
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Cost Effective ◽  
Cancer Services ◽  
Effective Option

scholarly journals Does the merger of two head and neck cancer services affect patient outcomes?

2017 ◽  
Vol 46 ◽  
pp. 130
Author(s):  
H. Mohamedbhai ◽  
S. Thomas ◽  
R. Nekrasius ◽  
L. Watson ◽  
C. Liew ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Patient Outcomes ◽  
Neck Cancer ◽  
Cancer Services

scholarly journals Current concepts of surveillance and its significance in head and neck cancer

2011 ◽  
Vol 93 (8) ◽  
pp. 576-582 ◽  
Author(s):  
Kapila Manikantan ◽  
Raghav C Dwivedi ◽  
Suhail I Sayed ◽  
KA Pathak ◽  
Rehan Kazi
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Cost Effective ◽  
Second Primary ◽  
Evidence Based ◽  
Significant Cost ◽  
Second Primary Tumours ◽  
Cost Implications

Follow-up in head and neck cancer (HNC) is essential to detect and manage locoregional recurrence or metastases, or second primary tumours at the earliest opportunity. A variety of guidelines and investigations have been published in the literature. This has led to oncologists using different guidelines across the globe. The follow-up protocols may have unnecessary investigations that may cause morbidity or discomfort to the patient and may have significant cost implications. In this evidence-based review we have tried to evaluate and address important issues like the frequency of follow-up visits, clinical and imaging strategies adopted, and biochemical methods used for the purpose. This review summarises strategies for follow-up, imaging modalities and key investigations in the literature published between 1980 and 2009. A set of recommendations is also presented for cost-effective, simple yet efficient surveillance in patients with head and neck cancer.

scholarly journals Chest CT and Whole-Body 18F-FDG PET Are Cost-Effective in Screening for Distant Metastases in Head and Neck Cancer Patients

2010 ◽  
Vol 51 (2) ◽  
pp. 176-182 ◽  
Author(s):  
C. A. Uyl-de Groot ◽  
A. Senft ◽  
R. de Bree ◽  
C. R. Leemans ◽  
O. S. Hoekstra
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Fdg Pet ◽  
Cost Effective ◽  
Distant Metastases ◽  
Chest Ct ◽  
Whole Body ◽  
18F Fdg

Evaluation of functional outcomes (speech, swallowing and voice) in patients attending speech pathology after head and neck cancer treatment(s): development of a multi-centre database

2000 ◽  
Vol 114 (8) ◽  
pp. 605-615 ◽  
Author(s):  
Alison R. Perry ◽  
Margaret A. Shaw
Keyword(s):  
Head And Neck Cancer ◽  
Data Collection ◽  
Head And Neck ◽  
Neck Cancer ◽  
Functional Outcomes ◽  
Speech Pathology ◽  
Cancer Treatments ◽  
Early Results ◽  
Cancer Services ◽  
Centre Database

Since April 1997, in Melbourne, Australia, speech pathologists have collaborated to establish a prospective database of functional outcomes of speech, swallowing and voice for patients undergoing head and neck cancer treatments.Staff at eight acute care hospitals, all of which offer speech pathology for head and neck cancer services in Victoria, are contributing data, collated centrally, in an agreed pro forma.Early results are given (after 12 months’ data collection). The implications for clinically-based research, and the future potential for benchmarking outcomes – by expansion of the rehabilitation database beyond the current participating sites – is discussed.This paper outlines the rationale of establishing the database is multicentred, and explores some of the complexities involved, including the challenges inherent in long-term accurate data collection in the head and neck cancer patient population. This work represents the development of an appropriate, usable tool for data collection on functional outcomes.

Altered fractionated radiotherapy is cost-effective in the treatment of locally advanced head and neck cancer: An economic analysis of Radiation Therapy Oncology Group (RTOG) 90–03

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 6007-6007
Author(s):  
A. A. Konski ◽  
M. Bhargavan ◽  
J. Owen ◽  
R. Paulus ◽  
J. Cooper ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Cost Effectiveness ◽  
Incremental Cost ◽  
Head And Neck ◽  
Neck Cancer ◽  
Locally Advanced ◽  
Radiation Therapy Oncology Group ◽  
Disease Free Survival ◽  
Cost Effective ◽  
Fractionated Radiotherapy

6007 Background: RTOG 9003 compared altered fractionated radiotherapy (AIFX) to standard radiotherapy (SFX). Overall and disease-free survival was improved in the AIFX schedules but with increased toxicity. The specific aim of this study was to compare the cost-effectiveness of AIFX to SFX. Methods: Costs data included Medicare Part A and Part B costs from all providers—inpatient, outpatient, skilled nursing facility, home health, hospice, and physicians and other Part B providers were obtained from the Centers for Medicare & Medicaid Services (CMS) for patients treated on RTOG 9003 from 1992–1996. Claims were restricted to those with a diagnosis of head and neck cancer. We calculated 56-month expected discounted costs for each arm of the trial in 1996 dollars, with Kaplan-Meier sampling average estimates of survival probabilities for each month and mean monthly costs. Costs were discounted back to the time of entry onto the trial, using an annual discount rate of 3% and indexed to 1996 dollars using the Consumer Price Index. The analysis was performed from a payer’s perspective. Incremental cost-effective ratios were calculated comparing AIFX schedules to SFX. Results: Of the 1,130 patients entered, 1,073 patients were analyzable for outcomes and Medicare cost data and clinical outcomes were available for 130 patients. The expected mean 56-month cost and incremental cost-effectiveness ratios (ICER) compared to SFX are presented in the table . Sensitivity analysis and 95% confidence ellipses will be presented. Conclusions: Although more toxic altered fractionated radiotherapy schedules were found to be cost-effective using a willingness to pay of $50,000/life year in patients >65 years old. These results need to be confirmed in a cohort of younger patients. [Table: see text] No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document